- Quest Diagnostics (DGX, Financial) achieved a 12.1% increase in Q1 2025 revenue, totaling $2.65 billion.
- Operating income rose 15.4% to $346 million with a 13.0% operating margin.
- Cash from operations more than doubled to $314 million, showcasing strong financial management.
Quest Diagnostics (DGX) reported a robust financial performance for the first quarter of 2025, with revenues reaching $2.65 billion, a notable increase of 12.1% compared to the same period in the previous year. The company's strategic endeavors resulted in a reported diluted EPS of $1.94, a 12.8% rise, and an adjusted diluted EPS of $2.21, marking an 8.3% improvement.
The company's Diagnostic Information Services revenues climbed by 12.7%, hitting $2.59 billion. Quest also reported a significant 15.4% increase in operating income, reaching $346 million, while improving its operating margin to 13.0% from 12.7% a year earlier.
Quest Diagnostics showcased exceptional cash flow management, with cash from operations more than doubling to $314 million, representing a substantial growth from $154 million in Q1 2024. This improvement underscores the company's efficiency in operational activities.
Quest reaffirmed its full-year 2025 guidance, projecting revenues between $10.70 billion and $10.85 billion, with an anticipated revenue growth of 8.4% to 9.9%. The company updated its reported diluted EPS guidance to $8.62-$8.87 and maintained its adjusted diluted EPS guidance of $9.55-$9.80.
CEO Jim Davis noted that the growth during the quarter was driven by acquisitions, increased demand for advanced diagnostics, and expanded health plan access, despite early-quarter adverse weather conditions.
